Homologous tumor‐targeting biomimetic nanozyme for synergistic NIR‐II photothermal and chemodynamic therapy

Read full text
Authors: X D Li, Siman Luo, Yucheng Zuo, Liheng Chen, Houjuan Zhu, Jingyi Zhu, Wei Xue
Cited by: 1
References: 54

Abstract

Abstract The therapeutic potential of nanozyme‐mediated chemodynamic therapy (CDT) is often hindered by limited catalytic efficiency and undesirable off‐target effects. To address these limitations, we engineered a cancer cell membrane‐coated Au‐MnO x nanozyme (Au‐MnO x @CCM) engineered for near‐infrared (NIR) enhanced tumor CDT. This multifunctional nanozyme exhibits both catalase‐like (CAT‐like) and peroxidase‐like (POD‐like) activities, enabling the in situ generation of oxygen (O 2 ) to alleviate tumor hypoxia and facilitate the production of cytotoxic hydroxyl radicals (•OH) for selective tumor cell eradication. Concurrently, the Au‐MnO x nanozyme effectively depletes intracellular glutathione (GSH), thereby amplifying oxidative stress and enhancing CDT efficacy. The biomimetic coating with homologous the cancer cell membrane (CCM) significantly improves tumor‐targeting specificity, reduces off‐target accumulation, prolongs systemic circulation, and minimizes immune clearance. Moreover, the application of NIR irradiation enables deep tissue penetration and precise spatial activation of the nanozyme at the tumor site, further enhancing therapeutic selectivity and potency. Collectively, this well‐designed Au‐MnO x @CCM nanozyme integrates CDT and photothermal therapy (PTT), offering a synergistic, tumor‐specific, and minimally invasive therapeutic strategy. This platform holds considerable promise for advancing precision oncology with improved therapeutic outcomes and reduced systemic toxicity.

Fields of Study & Subjects

Nanoplatforms for cancer theranostics Advanced Nanomaterials in Catalysis Cancer Research and Treatments

Publication details

Journal / source
BMEMat
Publisher
Wiley
Publication date
21 May 2026
Language
EN